Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: What's next?

Thrombosis and Haemostasis

Volumn 108, Issue 3, 2012, Pages 407-409

  Harenberg, Job ^a   Marx, Svetlana ^a   Wehling, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CREATININE CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; STROKE; THERAPY EFFECT; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; MALE; MORPHOLINES; MULTICENTER STUDIES AS TOPIC; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; THROMBOPHILIA;

EID: 84865823243     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-07-0463     Document Type: Editorial

References (26)

1. Roskell NS, et al Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. ThrombHaemost2010; 104: 1106-1115.
2. Hart RG, et al Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007; 147: 590-592.
3. Lip GY. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. J Thromb Haemost 2011; 9 (Suppll): 344-351.
4. 1 atrial fibrillation patients. Thromb Haemost 2011; 106: 34-44.
5. Wilke T, et al Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012; 107: 1053-1065.
6. Olesen JB, et al Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011; 106: 739-749.
7. Gallagher AM, et al Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106: 968-977.
8. Ahrens I, et al New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.
9. Connolly SJ, et al Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
10. Connolly SJ, et al Newly identified events in the RELY trial. N Engl J Med 2010; 363: 1875-1876.
11. Patel MR, et al Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
12. Granger CB, et al Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992.
13. Mantha S, Ansell J. An Indirect Comparison of Dabigatran, Rivaroxaban and Apixaban for Atrial Fibrillation. Thromb Haemost 2012; 108:476-484.
14. Glenny AM, et al Indirect comparisons of competing interventions. Health Technol Assess 2005; 9: 1-134, iii-iv.
15. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002; 21: 2313-2324.
16. Gage BF, et al Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005; 118:612-617.
17. Garcia DA, et al New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost 2010; 104:1099-1105.
18. Psaty BM, et al Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. J Am Med Assoc 2003;289:2534-2544.
19. Lip GY, et al Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation. J Am Coll Cardiol 2012; epub ahead of print.
20. Harenberg J, et al Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using networkmeta-analysis. Intern Angiol 2012; 31: 330-339.
21. Wells GA, et al Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation. Available at: http://wwwcadthca/media/pdf/NOACTherapeuticReviewfinalreportpdf. Accessed July 4th, 2012.
22. Gomez-Outes A, et al Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. Br Med J 2012; 344: e3675.
23. Cohen A, et al The Efficacy and Safety of Pharmacological Prophylaxis of Venous Thromboembolism Following Elective Knee or Hip Replacement: Systematic Review and Network Meta-Analysis. Clin Appl Thromb Hemost 2012; epub ahead of print.
24. Fadda V, et al Network meta-analysis. Results can be summarised in a simple figure. Br Med J 2011; 342:dl555.
25. Banerjee A, et al Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-589.
26. Kirchhof P, et al Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Thromb Haemost 2011; 106: 1012-1019.